Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction

Summary

Pharmacogenetic dosing algorithms help predict warfarin maintenance doses, but their predictive performance differs in different populations, possibly due to unsuspected population-specific genetic variants. The objectives of this study were to quantify the effect of the VKORC1 D36Y variant (a marker of warfarin resistance previously described in 4% of Ashkenazi Jews) on warfarin maintenance doses and to examine how this variant affects the performance of the International Warfarin Pharmacogenetic Consortium (IWPC) dose prediction model. In 210 Israeli patients on chronic warfarin therapy recruited at a tertiary care centre, we applied the IWPC model and then added D36Y genotype as covariate to the model (IWPC+D36Y) and compared predicted with actual doses. Median weekly warfarin dose was 35 mg (interquartile range [IQR], 24.5 to 52.5 mg). Among 16 heterozygous D36Y carriers (minor allele frequency = 3.8%), warfarin weekly dose was increased by a median of 43.7 mg (IQR, 40.5 to 47.2 mg) compared to non-carriers after adjustment for all IWPC parameters, a greater than two-fold dose increase. The IWPC model performed suboptimally (coefficient of determination R²=27.0%; mean absolute error (MAE), 14.4 ± 16.2 mg/ week). Accounting for D36Y genotype using the IWPC+D36Y model resulted in a significantly better model performance (R²=47.2%, MAE=12.6±12.4 mg/week). In conclusion, even at low frequencies, variants with a strong impact on warfarin dose may greatly decrease the performance of a commonly used dose prediction model. Unexpected discrepancies of the performance of universal prediction models in subpopulations should prompt searching for unsuspected confounders, including rare genetic variants.

Keywords

Warfarin - pharmacogenetics - VKORC1 - dose prediction - ethnicity

• References

• 1 Kurnik D, Loebstein R, Halkin H. et al. 10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. Pharmacogenomics 2009; 10: 1955-1965.
• 2 Johnson JA, Gong L, Whirl-Carrillo M. et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011; 90: 625-629.
• 3 Klein TE, Altman RB, Eriksson N. et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
• 4 Gage BF, Eby C, Johnson JA. et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84: 326-331.
• 5 Wadelius M, Chen LY, Lindh JD. et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113: 784-792.
• 6 Gong IY, Schwarz UI, Crown N. et al. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS One 2011; 06: e27808.
• 7 Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008; 83: 460-470.
• 8 Anderson JL, Horne BD, Stevens SM. et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116: 2563-2570.
• 9 Epstein RS, Moyer T P, Aubert RE. et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010; 55: 2804-2812.
• 10 Gong IY, Tirona RG, Schwarz UI. et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 2011; 118: 3163-3171.
• 11 Carlquist JF, Anderson JL. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation 2011; 124: 2554-2559.
• 12 FDA approves updated warfarin sodium label. Available at: http://www.fda.gov/Safety/MedWatch/SAfetyInformation/ucm201100.htm Last accessed on January 31, 2012. 2010.
• 13 Limdi NA, Wadelius M, Cavallari L. et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115: 3827-3834.
• 14 Botton MR, Bandinelli E, Rohde LE. et al. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol 2011; 72: 442-450.
• 15 Shin J, Cao D. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics 2011; 12: 125-134.
• 16 Takahashi H, Wilkinson GR, Nutescu EA. et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16: 101-110.
• 17 D'Ambrosio RL, D'Andrea G, Cafolla A. et al. A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme. J Thromb Haemost 2007; 05: 191-193.
• 18 Loebstein R, Dvoskin I, Halkin H. et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007; 109: 2477-2480.
• 19 Watzka M, Geisen C, Bevans CG. et al. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost 2011; 09: 109-118.
• 20 Bodin L, Perdu J, Diry M. et al. Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans. J Thromb Haemost 2008; 06: 1436-1439.
• 21 Vecsler M, Loebstein R, Almog S. et al. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 2006; 95: 205-211.
• 22 Loebstein R, Vecsler M, Kurnik D. et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther 2005; 77: 365-372.
• 23 Shaw PB, Donovan JL, Tran MT. et al. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic. J Thromb Thrombolysis 2010; 30: 220-225.
• 24 IWPC algorithm. Available at: http://www.pharmgkb.org/drug/PA451906 Last accessed on January 31. IWPC algorithm.
• 25 Caldwell MD, Awad T, Johnson JA. et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111: 4106-4112.
• 26 Ramirez AH, Shi Y, Schildcrout JS. et al. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 2012; 13: 407-418.
• 27 Scott SA, Edelmann L, Kornreich R. et al. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 2008; 82: 495-500.
• 28 Aklillu E, Leong C, Loebstein R. et al. VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood 2008; 111: 3903-3904.
• 29 Harrington DJ, Gorska R, Wheeler R. et al. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost 2008; 06: 1663-1670.
• 30 Shuen AY, Wong BY, Fu L. et al. Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic. Clin Biochem 2012; 45: 397-401.
• 31 Pavani A, Naushad SM, Rupasree Y. et al. Optimization of warfarin dose by population-specific pharmacogenomic algorithm. Pharmacogenomics J 2012; 12: 306-311.
• 32 Mitchell C, Gregersen N, Krause A. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics 2011; 12: 953-963.
• 33 Harrington DJ, Siddiq S, Allford SL. et al. More on: endoplasmic reticulum loop VKORC1 substitutions cause warfarin resistance but do not diminish gamma-carboxylation of the vitamin K-dependent coagulation factors. J Thromb Haemost 2011; 09: 1093-1095.
• 34 Suarez-Kurtz G. Population diversity and the performance of warfarin dosing algorithms. Br J Clin Pharmacol 2011; 72: 451-453.
• 35 Cooper GM, Johnson JA, Langaee TY. et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112: 1022-1027.
• 36 Zhang JE, Jorgensen AL, Alfirevic A. et al. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics 2009; 19: 781-789.
• 37 Perini JA, Struchiner CJ, Silva-Assuncao E. et al. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin Pharmacol Ther 2010; 87: 417-420.
• 38 Bejarano-Achache I, Levy L, Mlynarsky L. et al. Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study. Clin Ther 2012; 34: 811-823.
• 39 King CR, Deych E, Milligan P. et al. Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost 2010; 104: 750-754.
• 40 Cushman M, Booth SL, Possidente CJ. et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112: 572-577.
• 41 Braam L, McKeown N, Jacques P. et al. Dietary phylloquinone intake as a potential marker for a heart-healthy dietary pattern in the Framingham Offspring cohort. J Am Diet Assoc 2004; 104: 1410-1414.
• 42 Loebstein R, Yonath H, Peleg D. et al. Interindividual variability in sensitivity to warfarin-nature or nurture?. Clin Pharmacol Ther 2001; 70: 159-164.
• 43 Lurie Y, Loebstein R, Kurnik D. et al. Warfarin and vitamin K intake in the era of pharmacogenetics. Br J Clin Pharmacol 2010; 70: 164-170.
• 44 Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010; 104: 1099-1105.
• 45 Lip GY, Andreotti F, Fauchier L. et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.